Geron is a commercial-stage biopharmaceutical company focused on blood cancer treatment. Their FDA-approved telomerase inhibitor targets low-to-intermediate-risk myelodysplastic syndromes (MDS) and is being investigated in clinical trials for other hematologic malignancies, including myelofibrosis. The company’s innovative approach aims to reduce the proliferation of malignant cells in the bone marrow.